Samsung Biologics Co., Ltd. is a global contract development and manufacturing organization headquartered in Songdo, Incheon, South Korea. The biotech division of Samsung Group, its core services range from late discovery to large-scale commercial manufacturing. The company focuses on monoclonal antibodies, bispecific antibodies, antibody-drug conjugates, and mRNA vaccines.
 | |
| Company type | Public |
|---|---|
| KRX: 207940 | |
| Industry | Biopharmaceuticals |
| Founded | 2011 |
| Headquarters | , South Korea |
Area served | Worldwide |
Key people | John Rim (president and CEO)[1] |
| Revenue |  KRW 3.69 trillion (2023) [2] |
| KRW 1.11 trillion (2023)[2] | |
| Owners |
|
Number of employees | 4,300 (2023) |
| Subsidiaries | Samsung Bioepis |
| Korean name | |
| Hangul | 삼성바이오로직스 |
| Revised Romanization | Samseong Baiorojikseu |
| McCune–Reischauer | Samsŏng Paiorojiksŭ |
| Website | samsungbiologics |
The company has partnered with pharmaceutical companies such as Pfizer,[3] GlaxoSmithKline,[4] Eli Lilly,[5] AstraZeneca[6] and Bristol-Myers Squibb.[7]
History
editFacilities & Expansion
editFounded in 2011,[8] Samsung Biologics built four manufacturing plants with a capacity of more than 600,000 liters, from 2011 to 2023.[9][10][11] In 2023, Samsung Biologics began construction of a fifth plant in Incheon, South Korea. Once complete, the company’s five core facilities will hold up to 784,000 liters of biomanufacturing capacity.[12]
Since 2020, Samsung Biologics has expanded its United States operations, opening offices in New Jersey[13] and San Francisco[14] to more closely support U.S. biopharmaceutical companies across both coasts.
Notable Partnerships
editAs of June 2024, Samsung Biologics' CEO John Rim reported active partnerships with 16 of the top 20 largest biopharmaceutical companies.[15][16] This includes early deals with Roche[17] and Bristol-Myers Squibb[18] in 2013, through to large partnerships during and after the pandemic. In 2020, GSK and Samsung Biologics signed the first of two major agreements: a $231 million, eight-year deal to manufacture biological therapies, including the lupus drug Benlysta.[19] Two years later, a second $296 million deal was signed.[20]
During the COVID-19 pandemic, Samsung Biologics partnered with Moderna for fill-finish, packaging and labeling of its mRNA vaccine, Spikevax.[21][22] The company was also contracted to manufacture Eli Lilly's COVID-19 antibody therapeutic[23] and AstraZeneca's long-acting antibody therapeutic as part of a larger multi-product deal.[24]
In June 2023, Samsung Biologics entered a partnership with Pfizer for the commercial manufacturing of Pfizer’s multi-product biosimilars portfolio in a deal worth $411 million.[3] A month later, Samsung Biologics entered two deals with Pfizer worth a combined $897 million to produce biosimilar products ranging from oncology and inflammation to immunotherapy at its Plant 4.[25]
Along with Big pharma partnerships, the company has engaged with smaller development-stage companies. In 2023, Samsung Biologics announced a multi-year agreement with European venture capital firm Kurma Partners to support its portfolio companies through development, manufacturing, and de-risking services.[26] In February 2024, Samsung Biologics announced a partnership agreement with LigaChem (formerly LegoChem) Biosciences to provide antibody development and drug substance manufacturing services to support LigaChem's antibody-drug conjugate (ADC) pipeline.[27]
Samsung Biologics signed a 1.7 trillion won ($1.2 billion) deal with an unnamed Asian pharmaceutical company to provide contract manufacturing organization services, the largest contract secured in the company's history.[28]
Business Ventures
editIn 2012, it established Samsung Bioepis, a biosimilar medicine developer, as a joint venture with Biogen.[29] The company acquired full ownership of Samsung Bioepis in 2022 by purchasing all remaining shares from Biogen for $2.3 billion.[30]
In 2021, the Samsung Life Science Fund was created through a joint partnership between Samsung Biologics, Samsung Bioepis, and Samsung C&T.[31] The fund, managed by Samsung Ventures, aims to foster the growth of next-generation technologies, such as gene therapies and ADCs.
Samsung Bioepis’s biosimilar product Opuviz has been approved by the European Commission, according to the Korean biosimilar developer on Nov. 2024.[32]
Platforms
editSamsung Biologics has developed a range of proprietary technologies for biologics development. This includes S-CHOice, a cell line expression technology introduced in 2020.[33] In 2022, Samsung Biologics launched S-DUAL, a bispecific antibody platform,[34] and its DEVELOPICK platform, a service that selects candidate materials for new drugs.
Sustainability
editSamsung Biologics published its first annual sustainability report in June 2021. It was added to the Dow Jones Sustainability World Index later that year.[35]
Samsung Biologics was awarded the Sustainable Market Initiative's 2022 Terra Carta Seal, which recognizes global companies driving innovation and action towards the creation of genuinely sustainable markets.[36]
In 2023, Samsung Biologics received both a leadership A- score from the Carbon Disclosure Project (CDP)[37] and an EcoVadis Platinum Sustainability Rating,[38] placing the company in the top one percent of over 100,000 companies assessed by EcoVadis.
See also
editReferences
edit- ^ "Samsung Biologics names John Rim as new chief". The Korea Times. 17 December 2020.
- ^ a b "Samsung Biologics Surpasses 1 Trillion Won in Annual Operating Profit for 1st Time". BusinessKorea. 25 January 2024.
- ^ a b biopharma-reporter.com (2023-06-12). "Samsung Biologics inks biosimilar manufacturing deal with Pfizer". biopharma-reporter.com. Retrieved 2023-06-14.
- ^ Dunleavy, Kevin (21 October 2022). "GSK and Samsung Bio double down with 2nd manufacturing deal, this one for $296M". Fierce Pharma. Retrieved 22 July 2024.
- ^ Sagonowsky, Eric (17 November 2020). "Lilly partners with Samsung to boost COVID-19 antibody manufacturing amid supply concerns". Fierce Pharma. Retrieved 22 July 2024.
- ^ Blankenship, Kyle (22 September 2020). "AstraZeneca, Samsung reach $331M biologics manufacturing deal amid Korean CMO's expansion push". Fierce Pharma. Retrieved 22 July 2024.
- ^ Lynch, Connor (18 September 2023). "Samsung Biologics Strikes $242M Manufacturing Deal with BMS for Cancer Antibody". BioSpace. Retrieved 22 July 2024.
- ^ "Blazing Samsung Biologics trail into new territory". The Korea Herald. 30 January 2020.
- ^ "Samsung BioLogics annual sales up 30% on contract research growth". Korea Biomedical Review. 23 January 2020.
- ^ "Samsung Biologics to add new contract drug-making plant". The Korea Times. 20 March 2020.
- ^ Manalac, Tristan (5 July 2023). "Pfizer Inks Manufacturing Deals with Samsung Biologics Worth Nearly $900M". www.biospace.com.
- ^ "Samsung Biologics to Build Plant 5 as Part of Capacity Expansion to Bio Campus II". BioPharm International. 21 March 2023.
- ^ Han-na, Park (6 June 2023). "[Bio USA] Samsung Biologics seeks giant leap with new plant, ADC tech". The Korea Herald.
- ^ Dan Stanton (16 June 2020). "Samsung Biologics selects San Francisco for first US facility". BioProcess International.
- ^ Ha-Nee, Shin (7 June 2024). "Business soars for Korean pharma as U.S. cuts ties with Chinese partners". Korea JoongAny Daily.
- ^ Ahn, Dae-Kyu (7 June 2024). "Samsung Biologics eyes windfall gain amid US-China row". The Korean Economic Daily.
- ^ Tyler, Dominic (24 October 2013). "Roche signs biologics partnership with Samsung". PMLiVE.
- ^ Thomas, Felicity (20 September 2023). "Samsung Biologics Expands Strategic Manufacturing Agreement with Bristol Myers Squibb". Pharmaceutical Technology.
- ^ Liu, Angus (22 May 2020). "GlaxoSmithKline hands Samsung Biologics $231M to scale up manufacturing". Fierce Pharma.
- ^ Dunleavy, Kevin (21 October 2022). "GSK and Samsung Bio double down with 2nd manufacturing deal, this one for $296M". Fierce Pharma.
- ^ "Moderna taps Samsung for fill-finish duties on 'hundreds of millions' of COVID-19 vaccine doses". Fierce Pharma.
- ^ "Samsung Biologics, GreenLight to produce COVID vaccine for Africa". The Korea Herald.
- ^ Stanton, Dan (23 November 2020). "Samsung Bio in $150m deal to make COVID antibodies for Lilly". BioProcess International.
- ^ Keenan, Joseph (14 December 2021). "Samsung Biologics, AstraZeneca expand manufacturing partnership to add COVID and cancer therapies". Fierce Pharma.
- ^ Yim, Hyunsu (4 July 2023). "Samsung Biologics unveils $897 million manufacturing deals for Pfizer". Reuters.
- ^ Nelson, Millie (30 October 2023). "Samsung Biologics strikes manufacturing and development deal with Kurma". BioProcess International.
- ^ Keenan, Joseph (7 February 2024). "Samsung Biologics, LegoChem partner to propel ADC development and production". Fierce Pharma.
- ^ "Samsung Biologics signs largest-ever $1.2 billion deal". Korea JoongAng. 2024.
- ^ "Samsung BioLogics no longer a holding company of Samsung Bioepis". The Korea Herald. 5 April 2019.
- ^ Angus Liu (28 January 2022). "Samsung buys Biogen out of biosimilar unit for $2.3B—not the whole Aduhelm headache". Fierce Pharma.
- ^ "Samsung's Life Science Fund invests in US biotech Jaguar Gene Therapy". The Korea Economic Daily. 30 March 2022.
- ^ "Samsung Bioepis's Opuviz gets EC approval". Korea JoongAng. 2024.
- ^ Jeong-yeo, Lim (5 August 2020). "Samsung Biologics launches S-CHOice cell line expression technology". The Korea Herald.
- ^ Byung-yeul, Baek (7 October 2022). "Samsung Biologics launches bispecific antibody platform S-DUAL". Korea Times.
- ^ "Six Korean companies added to Dow Jones Sustainability World Index". The Korea Herald.
- ^ Eckford, Catherine. "2022 Terra Carta Seal: three pharma companies awarded". European Pharmaceutical Review.
- ^ Byung-yeul, Baek (13 February 2024). "Samsung Biologics recognized for response to climate change". The Korea Times.
- ^ Choi, Jasmine (23 January 2024). "Samsung Biologics Achieves Top 'Platinum' Rating in EcoVadis ESG Evaluation". Business Korea.
External links
edit- Official website
- Business data for Samsung Biologics: